Interleukin-6 in Plaque Psoriasis and Its Possible Role in Disease Severity

Tanta University

Status: Completed

Conditions: Disease Severity; Plaque Psoriasis; Interleukin-6

Treatments: Other: Enzyme-linked immunosorbent assay (ELISA)

Study type: Observational

Funder types: Other

Identifiers

NCT07001904

36264MS308/9/23

Details and patient eligibility

About

This study aimed to evaluate serum IL-6 levels in plaque psoriasis patients and investigate their correlation with disease severity.

Full description

Psoriasis is a chronic, immune-mediated inflammatory dermatological condition that impacts around 0.2% to 4.8% of the worldwide population.

Interleukin (IL)-6 is a pleiotropic cytokine that regulates immunity, hematopoiesis, and inflammation. It is produced by keratinocytes, endothelial cells, fibroblasts, and immune cells like macrophages and dendritic cells. Increased IL-6 expression has been observed in psoriatic lesions, suggesting its involvement in disease pathogenesis

Enrollment: 50 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age above 18 years.
• Both sexes.
• Patients clinically diagnosed with plaque psoriasis.

Exclusion criteria

• Patients who had received any treatment for psoriasis in the last three months.
• Patients with other types of psoriasis.
• Those currently receiving systemic treatment.
• Individuals with other inflammatory diseases.
• Pregnant or lactating women.
• Those using contraceptive pills.
• Patients with metabolic conditions like diabetes mellitus or thyroid disorders.

Trial design

50 participants in 2 patient groups

Patients group

Description:

Patients with plaque psoriasis.

Treatment:

Other: Enzyme-linked immunosorbent assay (ELISA)

Control group

Description:

Sex- and age-matched healthy control individuals.

Treatment:

Other: Enzyme-linked immunosorbent assay (ELISA)